FcRn Blocker Offers Hope to gMG Patients ‘Left Out in Cold’

19 Oct 2026 0 comments

Patients with gMG who lack detectable anti-AChR antibodies — a group historically excluded from clinical trials — show sustained benefits with efgartigimod.
Medscape Medical News

Source: Medscape Neurology Published 19 Oct 2026 Imported 19 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment